Clozapine
Clozaril, Versacloz (clozapine) is a small molecule pharmaceutical. Clozapine was first approved as Clozaril on 1989-09-26. It is used to treat bipolar disorder, psychotic disorders, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. The pharmaceutical is active against D(2) dopamine receptor and 5-hydroxytryptamine receptor 2A. In addition, it is known to target D(1B) dopamine receptor, 5-hydroxytryptamine receptor 1F, 5-hydroxytryptamine receptor 6, alpha-1D adrenergic receptor, 5-hydroxytryptamine receptor 1A, alpha-1B adrenergic receptor, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 1D, alpha-1A adrenergic receptor, 5-hydroxytryptamine receptor 1B, D(1A) dopamine receptor, muscarinic acetylcholine receptor M1, 5-hydroxytryptamine receptor 2C, histamine H1 receptor, 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 7, D(4) dopamine receptor, histamine H4 receptor, D(3) dopamine receptor, G protein-activated inward rectifier potassium channel 2, and histamine H3 receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Clozaril, Versacloz (generic drugs available since 1997-11-26, discontinued: Fazaclo)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bipolar disorder | EFO_0000289 | D001714 | F30.9 |
| psychotic disorders | — | D011618 | F20.81 |
| schizophrenia | EFO_0000692 | D012559 | F20 |
| schizophrenia spectrum and other psychotic disorders | — | D019967 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Clozapine, Versacloz, Tasman Pharma | |||
| 8057811 | 2028-05-01 | DP | |
HCPCS
Code | Description |
|---|---|
| S0136 | Clozapine, 25 mg |
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 3 | 2 | 3 | 1 | 9 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | — | 1 | — | 1 |
| Drug resistant epilepsy | D000069279 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myoclonic epilepsies | D004831 | EFO_1001900 | G40.4 | — | — | 2 | — | — | 2 |
| Seizures | D012640 | G40.4 | — | 1 | 1 | — | — | 2 | |
| Generalized epilepsy | D004829 | — | 1 | 1 | — | — | 2 | ||
| Dementia | D003704 | F03 | — | — | 1 | — | — | 1 | |
| Psychophysiologic disorders | D011602 | F45.9 | — | — | 1 | — | — | 1 | |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | — | 1 |
| Depression | D003863 | F33.9 | — | — | 1 | — | — | 1 | |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Low back pain | D017116 | HP_0003419 | M54.5 | — | — | 1 | — | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuralgia | D009437 | EFO_0009430 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CLOZAPINE |
| INN | clozapine |
| Description | Clozapine is a benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia. It has a role as a serotonergic antagonist, a dopaminergic antagonist, an adrenergic antagonist, a histamine antagonist, a muscarinic antagonist, a second generation antipsychotic, a GABA antagonist, an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor, a xenobiotic and an environmental contaminant. It is a benzodiazepine, a N-methylpiperazine, a N-arylpiperazine and an organochlorine compound. |
| Classification | Small molecule |
| Drug class | tricyclic compounds |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 5786-21-0 |
| RxCUI | 2626 |
| ChEMBL ID | CHEMBL42 |
| ChEBI ID | 3766 |
| PubChem CID | 135398737 |
| DrugBank | DB00363 |
| UNII ID | J60AR2IKIC (ChemIDplus, GSRS) |
Target
Alternate
DRD5
DRD5
HTR1F
HTR1F
HTR6
HTR6
ADRA1D
ADRA1D
HTR1A
HTR1A
ADRA1B
ADRA1B
HTR2B
HTR2B
HTR5A
HTR5A
HTR1D
HTR1D
ADRA1A
ADRA1A
HTR1B
HTR1B
DRD1
DRD1
CHRM1
CHRM1
HTR2C
HTR2C
HRH1
HRH1
HTR1E
HTR1E
HTR7
HTR7
DRD4
DRD4
HRH4
HRH4
DRD3
DRD3
KCNJ6
KCNJ6
HRH3
HRH3
Variants
Clinical Variant
No data
Financial
Fazaclo - Jazz Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 23,547 documents
View more details
Safety
Black-box Warning
Black-box warning for: Clozaril, Versacloz
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
8,609 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more